| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | EPSTI1 |
| Uniprot No | Q96J88 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-318aa |
| 氨基酸序列 | MNTRNRVVNS GLGASPASRP TRDPQDPSGR QGELSPVEDQ REGLEAAPKG PSRESVVHAG QRRTSAYTLI APNINRRNEI QRIAEQELAN LEKWKEQNRA KPVHLVPRRL GGSQSETEVR QKQQLQLMQS KYKQKLKREE SVRIKKEAEE AELQKMKAIQ REKSNKLEEK KRLQENLRRE AFREHQQYKT AEFLSKLNTE SPDRSACQSA VCGPQSSTWK LPILPRDHSW ARSWAYRDSL KAEENRKLQK MKDEQHQKSE LLELKRQQQE QERAKIHQTE HRRVNNAFLD RLQGKSQPGG LEQSGGCWNM NSGNSWGI |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于EPSTI1重组蛋白的3篇参考文献及其摘要概括：
1. **"EPSTI1 promotes breast cancer metastasis through interleukin-6-mediated tumor microenvironment remodeling"**
*作者：Zhang Y, et al.*
摘要：研究发现重组EPSTI1蛋白通过激活IL-6/STAT3信号通路，诱导肿瘤相关巨噬细胞浸润，促进乳腺癌细胞侵袭和转移。
2. **"Recombinant EPSTI1 protein induces EMT and enhances stemness in pancreatic cancer cells"**
*作者：Li H, et al.*
摘要：通过体外实验证明，重组EPSTI1蛋白可激活TGF-β通路，诱导上皮-间质转化(EMT)，并增强胰腺癌细胞的干性特征，促进化疗耐药。
3. **"EPSTI1 as a novel regulator of innate immunity: Role in viral infection response"**
*作者：Wang X, et al.*
摘要：首次报道重组EPSTI1蛋白通过调控干扰素产生，增强宿主抗病毒免疫反应，为病毒感染治疗提供潜在靶点。
4. **"EPSTI1 recombinant protein suppresses osteosarcoma progression by inhibiting angiogenesis"**
*作者：Chen L, et al.*
摘要：动物实验显示，外源性重组EPSTI1蛋白通过下调VEGF表达，抑制骨肉瘤血管生成，显著延缓肿瘤生长。
注：以上文献信息为示例性内容，实际文献需通过学术数据库(如PubMed、Web of Science)检索确认。
EPSTI1 (Epithelial Stromal Interaction 1) is a secreted protein encoded by the EPSTI1 gene, initially identified for its role in mediating crosstalk between epithelial cells and the tumor microenvironment. Though structurally distinct, it shares homology with the SERPIN superfamily. EPSTI1 is upregulated in various cancers, including breast, liver, and gastric cancers, and is linked to tumor progression, metastasis, and epithelial-mesenchymal transition (EMT). It promotes invasiveness by modulating extracellular matrix (ECM) remodeling, activating metalloproteinases (MMPs), and interacting with signaling pathways like NF-κB and STAT3. Beyond oncology, EPSTI1 participates in viral infections (e.g., influenza, hepatitis C) and immune regulation, where it influences interferon production and inflammatory responses.
Recombinant EPSTI1 protein is produced using expression systems (e.g., E. coli, mammalian cells) to study its biological functions. Purified via affinity chromatography, it retains bioactivity for in vitro assays, such as investigating cell migration, immune modulation, or protein interactions. Research applications include exploring its role as a therapeutic target, diagnostic biomarker, or tool for antibody development. Recent studies also highlight its potential in autoimmune and inflammatory diseases. Despite progress, its precise molecular mechanisms and context-dependent roles in different pathologies remain under investigation, driving ongoing interest in recombinant EPSTI1 for both basic and translational research.
×
